The CCRIFX is clearly meeting a critical subset of CCR bioinformatics needs, and the staff is continually improving the level of analysis support to the CCR community. It has become increasingly clear that most investigators have vastly underestimated the complexity involved with NGS analysis. The CCRIFX has positioned itself as the central resource for the analysis of NGS data. This is reflected in the fact that the number of publications involving the core's analysis is on the rise. At the end of 2011, the core was involved in one manuscript in development. As of March of this year (2013), the core is actively working as coauthors on at least 6 manuscripts with several more emerging as strong possibilities as research efforts mature. In addition, the core contributed as co-authors on 4 posters and was acknowledged in 2 manuscripts. Investigators have confirmed through post-service evaluations that the CCRIFX is helping to advance research efforts, contribute creativity and innovative thought as well as have a favorable impact on future publications. As expected, the sequencing technologies supported emphasize NGS as well as microarray technologies. A significant majority of requests involve data produced in-house. A substantial number of requests require external consultation with experts outside the core. Both ABCC and CCR bioinformatics personnel have provided critical expertise in regularly scheduled prioritization, status, and science meetings.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Scientific Cores Intramural Research (ZIC)
Project #
Application #
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
National Cancer Institute Division of Basic Sciences
Zip Code
Rothermel, Luke D; Sabesan, Arvind C; Stephens, Daniel J et al. (2016) Identification of an Immunogenic Subset of Metastatic Uveal Melanoma. Clin Cancer Res 22:2237-49
Dine, Jennifer L; O'Sullivan, Ciara C; Voeller, Donna et al. (2016) The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl. Breast Cancer Res Treat 155:235-51
Limou, Sophie; Nelson, George W; Lecordier, Laurence et al. (2015) Sequencing rare and common APOL1 coding variants to determine kidney disease risk. Kidney Int 88:754-63
Peretti, Alberto; FitzGerald, Peter C; Bliskovsky, Valery et al. (2015) Hamburger polyomaviruses. J Gen Virol 96:833-9
He, Ximiao; Tillo, Desiree; Vierstra, Jeff et al. (2015) Methylated Cytosines Mutate to Transcription Factor Binding Sites that Drive Tetrapod Evolution. Genome Biol Evol 7:3155-69
Kasembeli, Alex N; Duarte, Raquel; Ramsay, Michèle et al. (2015) APOL1 Risk Variants Are Strongly Associated with HIV-Associated Nephropathy in Black South Africans. J Am Soc Nephrol 26:2882-90
Castro, Nadia P; Fedorova-Abrams, Natalie D; Merchant, Anand S et al. (2015) Cripto-1 as a novel therapeutic target for triple negative breast cancer. Oncotarget 6:11910-29
Dummer, Patrick D; Limou, Sophie; Rosenberg, Avi Z et al. (2015) APOL1 Kidney Disease Risk Variants: An Evolving Landscape. Semin Nephrol 35:222-36
Johnson, Randall C; Nelson, George W; Zagury, Jean-Francois et al. (2015) ALDsuite: Dense marker MALD using principal components of ancestral linkage disequilibrium. BMC Genet 16:23
Limou, Sophie; Dummer, Patrick D; Nelson, George W et al. (2015) APOL1 toxin, innate immunity, and kidney injury. Kidney Int 88:28-34

Showing the most recent 10 out of 28 publications